Immunosenescence in multiple sclerosis: the identification of new therapeutic targets

The number of elderly multiple sclerosis (MS) patients is growing, mainly due to the increase in life expectancy general population and availability effective disease-modifying treatments. However, current treatments reduce frequency relapses slow progression disease, but they cannot stop disability accumulation associated with disease progression. One possible explanation impact immunosenescence, which unusual immune cell subsets that are thought have a role development an early ageing process autoimmunity. Here, we provide recent overview how senescence affects function it involved pathogenesis autoimmune diseases, particularly MS. Numerous studies demonstrated age-related changes experimental encephalomyelitis models, premature onset immunosenescence has been MS patients. Therefore, potential therapeutic strategies based on rejuvenating system proposed. Senolytics regenerative using haematopoietic stem cells, therapies oligodendrocyte precursor microglia monocytes, thymus cells senescent B T capable reversing could beneficial